Pharmafile Logo
Pharmafocus logo
Advanced Search

Teva

Showing 15 posts of 234 posts found.

sicorbio

Teva antihypertensive generic duo gets FDA thumbs up

November 7, 2016
Manufacturing and Production, Sales and Marketing Azor, FDA, Teva, Tribenzor

Teva has received the approval from the US Food and Drug Administration (FDA) for its generic hypertension treatments Tribenzor (olmesartan …

News
teva_copy

Teva sets out to delay generic competitor to Copaxone

October 31, 2016
Sales and Marketing Copaxone, Teva, Teva Pharmaceutical, generics

Teva Pharmacetuical, the Israel-based pharmaceutical company, submitted a document to the FDA on 30 October; the document outlines the differences …

News
allergan

Allergan in $200 million purchase of biopharmaceutical

October 28, 2016
Medical Communications Allergan, Motus Therapeutics, Rythm Holding, Teva

Allergan will acquire Motus Therapeautics, a biopharmaceutical company that specialises in developing treatments for gastroparesis. It is another acquisition that …

News
ipos0_l

Regeneron and Teva’s experimental drug halted by FDA clinical hold

October 17, 2016
Manufacturing and Production Regeneron, Teva, back pain, osteoarthritis

Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …

News
teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …

Appointment
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.

News
shutterstock_273326141

Teva and Regeneron team up for $2.6 billion pain treatment development

September 21, 2016
Research and Development, Sales and Marketing Regeneron, Teva, fasinumab, osteoarthritis

Teva and Regeneron have entered an agreement worth up to $2.6 billion to develop and market the latter’s experimental nerve …

News
c_gajus_-_fotolia

Teva and Intel team up to tackle Huntington’s with wearable tech

September 16, 2016
Medical Communications Huntington's, Intel, Teva, wearable tech

Israeli pharma firm Teva is joining forces with technology giant Intel to tackle the debilitating disease Huntington’s with cutting-edge wearable …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

September 9, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis

It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …

News
teva_copy

Teva to lay off 236 in Pomona, New York

August 30, 2016
Manufacturing and Production, Research and Development Teva, closure

Teva is currently in the process of winding down operations at its manufacturing plant in Pomona, New York as it …

News
teva_copy

Teva loses patent protection on lucrative MS treatment

August 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …

News
teva_copy

EU grants marketing authorisation for Teva’s asthma drug Cinqaero

August 19, 2016
Medical Communications, Sales and Marketing EU, Teva, approval, asthma, cinqaero, eosinophilic

The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

August 5, 2016
Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …

News
teva_copy

Teva completes $40 billion acquisition of Actavis Generics

August 3, 2016
Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics

Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …

News
ema_building_face_web

Flawed studies at Semler Research Centre calls for suspension of medicines, EMA recommends

July 25, 2016
Manufacturing and Production, Sales and Marketing EMA, Novartis, Teva, manufacturing, semler

Following an FDA inspection and WHO investigation earlier this year, the European Medicines Agency (EMA) has recommended the suspension of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026